Senores Pharmaceuticals Ltd.

As of June 30, 2026, Senores Pharmaceuticals Ltd. carries a market capitalization of 61.50B, placing it among publicly traded companies globally. Its enterprise value stands at 61.50B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Senores Pharmaceuticals Ltd.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Senores Pharmaceuticals Ltd. has 46.05M shares outstanding.

As of June 30, 2026, Senores Pharmaceuticals Ltd. trades at a trailing price-to-earnings ratio of 47.32.

As of June 30, 2026, Senores Pharmaceuticals Ltd. trades at an EV/EBITDA multiple of 30.04 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 9.13 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 36.27 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 61.50B versus a market cap of 61.50B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 23.97M in revenue per employee across its workforce of 281.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Senores Pharmaceuticals Ltd. recorded 412.70M in income tax expense. That works out to an effective tax rate of 23.98, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.72B, leaving 1.26B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Senores Pharmaceuticals Ltd.'s stock has gained approximately 60.21% over the past 52 weeks. The 50-day moving average sits at 1,410.60, while the 200-day moving average is 1,102.20.

Over the twelve months ended June 30, 2026, Senores Pharmaceuticals Ltd. generated 6.74B in revenue and converted that into 1.26B in net income, yielding earnings per share of 29.20. EBITDA reached 2.05B, while operating income came in at 1.70B.

Over the twelve months ended June 30, 2026, Senores Pharmaceuticals Ltd. posted a gross margin of 61.99, reflecting its pricing power and cost economics. The operating margin of 25.17 and net profit margin of 18.76 provide insight into operational efficiency.